Sergliflozin etabonate

Research use only, not for human use.

Sergliflozin etabonate, a SGLT-2 inhibitor, is used potentially for the treatment of type 2 diabetes and obesity.

Sergliflozin etabonate, a SGLT-2 inhibitor, is used potentially for the treatment of type 2 diabetes and obesity.

——

Animal Model:14 weeks, Female KK-Ay mice Dosage:1, 3, 10, 30 mg/kg Administration:Oral; once Result:Significantly reduced non-fasting blood glucose level with the reduction in blood glucose level at 2 h post dosing in the 1 mg/kg group, 3 mg/kg group, 10 mg/kg group, and 30 mg/kg group was 12, 15, 28, and 39%, respectively.Animal Model:4 weeks, Female KK-Ay mice Dosage:1.7, 8.4, 45.7 mg/kg in the 0.001, 0.005, and 0.025% sergliflozin etabonate Administration:Fed, daily for 9 weeks Result:Reduced non-fasting blood glucose level and decreased triglyceride content in the liver in a dose-dependent manner in diabetic control KK-Ay mice.

GW-869682 | GW-869682X | KGT-1251 | GW869682 | GW869682X | KGT1251 |

Others

Other Targets

protoporphyrinogen oxidase

——

——

408504-26-7

448.468

C23H28O9

>98% (HPLC)

——

CCOC(=O)OC[C@H]1O[C@@H](Oc2ccccc2Cc2ccc(OC)cc2)[C@H](O)[C@@H](O)[C@@H]1O

——

(-20℃)

With Ice Pack

≥ 2 years